Glenmark Pharmaceuticals receives ANDA approval for Amphetamine Sulfate Tablets USP, 5 mg and 10 mg

Glenmark Pharmaceuticals Limited (Glenmark) has received final approval by the United States Food & Drug Administration (U.S. FDA) for Amphetamine Sulfate Tablets USP, 5 mg and 10 mg, the generic version of Evekeo®1 Tablets, 5 mg and 10 mg, of Arbor Pharmaceuticals, LLC.

According to IQVIATM sales data for the 12 month period ending November 2020, the Evekeo® Tablets, 5 mg and 10 mg market2 achieved annual sales of approximately $21.5 million*.

Glenmark's current portfolio consists of 168 products authorized for distribution in the U.S. marketplace and 43 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Shares of GLENMARK PHARMACEUTICALS LTD. was last trading in BSE at Rs.485.5 as compared to the previous close of Rs. 491.3. The total number of shares traded during the day was 69737 in over 1863 trades.

The stock hit an intraday high of Rs. 495.7 and intraday low of 483.05. The net turnover during the day was Rs. 34265121.

1All brand names and trademarks are the property of their respective owners.

2Market includes brand and all available therapeutic equivalents

*IQVIA™ National Sales Perspectives: Retail & Non-Retail, November 2020

Source : Equity Bulls

Keywords